Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Compugen Ltd (CGEN)

Compugen Ltd (CGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,213,086
  • Shares Outstanding, K 68,420
  • Annual Sales, $ 712 K
  • Annual Income, $ -27,340 K
  • 60-Month Beta 2.73
  • Price/Sales 2,411.24
  • Price/Cash Flow N/A
  • Price/Book 9.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.09
  • Number of Estimates 6
  • High Estimate -0.08
  • Low Estimate -0.10
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.26 +23.82%
on 09/04/20
19.90 -11.31%
on 08/26/20
-1.28 (-6.76%)
since 08/21/20
3-Month
13.78 +28.08%
on 06/29/20
19.90 -11.31%
on 08/26/20
+1.17 (+7.13%)
since 06/22/20
52-Week
3.83 +361.12%
on 10/18/19
19.90 -11.31%
on 08/26/20
+13.16 (+293.10%)
since 09/20/19

Most Recent Stories

More News
Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody

HOLON, , /PRNewswire/ --  (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the Phase...

CGEN : 17.65 (-0.45%)
Compugen to Present at Upcoming September 2020 Investor Conferences

HOLON, , /PRNewswire/ --  (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the...

CGEN : 17.65 (-0.45%)
Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent

HOLON, , /PRNewswire/ --  (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO)...

CGEN : 17.65 (-0.45%)
4 Biotech Stocks Under $20 Analysts Love

The biotech industry has been on a tear as the search for coronavirus treatments heat up. Here are four biotech stocks that analysts love: Compugen (CGEN), Cerus (CERS), Mersana Therapeutics (MRSN) and...

CGEN : 17.65 (-0.45%)
CERS : 6.24 (+0.81%)
MRSN : 20.86 (-4.00%)
PTGX : 21.18 (+0.47%)
The Global Computational Biology Market is expected to grow from USD 2,709.47 Million in 2019 to USD 6,674.35 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 16.21%

, /PRNewswire/ -- Read the full report: The Global Computational Biology Market is expected to grow from in 2019 to by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 16.21%.Market Segmentation...

CGEN : 17.65 (-0.45%)
DASTY : 186.1299 (-0.31%)
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor

HOLON, , /PRNewswire/ -- (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration has cleared...

CGEN : 17.65 (-0.45%)
Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort

HOLON, , /PRNewswire/ --  (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the monotherapy...

CGEN : 17.65 (-0.45%)
Is the Options Market Predicting a Spike in Compugen (CGEN) Stock?

Investors need to pay close attention to Compugen (CGEN) stock based on the movements in the options market lately.

CGEN : 17.65 (-0.45%)
How Compugen (CGEN) Stock Stands Out in a Strong Industry

Compugen (CGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

CGEN : 17.65 (-0.45%)
Compugen Reports First Quarter 2020 Results

HOLON, , /PRNewswire/ --  (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the first quarter ended .

CGEN : 17.65 (-0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CGEN with:

Business Summary

Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas...

See More

Key Turning Points

2nd Resistance Point 18.60
1st Resistance Point 18.13
Last Price 17.65
1st Support Level 17.25
2nd Support Level 16.84

See More

52-Week High 19.90
Last Price 17.65
Fibonacci 61.8% 13.76
Fibonacci 50% 11.86
Fibonacci 38.2% 9.97
52-Week Low 3.83

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar